Skip to content
Main Menu
Science
Menu Toggle
Autologous Cellular Therapy
MSC-NTF Cells
MSC-NTF Cell Production
Publications
Pipeline
Menu Toggle
Pipeline
Pipeline Overview
Patients & Caregivers
Menu Toggle
About ALS
Clinical Trials
Preapproval Access Policies
Resources
About
Menu Toggle
Leadership
Menu Toggle
Executive Team
Board of Directors
Scientific Advisory Board
Careers
Investors & Media
Menu Toggle
Overview
News
Events and Presentations
Stock Information
Financial Reports & Filings
Corporate Governance
Contact
Main Menu
Science
Menu Toggle
Autologous Cellular Therapy
MSC-NTF Cells
MSC-NTF Cell Production
Publications
Pipeline
Menu Toggle
Pipeline
Pipeline Overview
Patients & Caregivers
Menu Toggle
About ALS
Clinical Trials
Preapproval Access Policies
Resources
About
Menu Toggle
Leadership
Menu Toggle
Executive Team
Board of Directors
Scientific Advisory Board
Careers
Investors & Media
Menu Toggle
Overview
News
Events and Presentations
Stock Information
Financial Reports & Filings
Corporate Governance
Contact
View All Articles
NurOwn® Phase 2 ALS Trial: ALSFRS-R Improvement is Reflected in Subscale Domains
Presented at the Annual AAN Meeting
Scroll to Top
